.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
STRIVE was a large randomized placebo-controlled trial evaluating erenumab, a monoclonal antibody against the CGRP receptor, for prevention of episodic migraine. More than 950 adults were assigned to monthly erenumab 70 mg, 140 mg or placebo for six months. Both doses produced a greater reduction in monthly migraine days than placebo, increased the proportion of patients achieving at least a 50% reduction and reduced use of acute migraine-specific medication. Improvements were also seen in migraine-related physical impairment and everyday activities. Adverse-event rates were similar to placebo in the trial. The study helped establish CGRP-pathway therapy as an effective preventive option for patients with frequent episodic migraine. For HCPs, treatment choice should consider attack burden, prior preventive failures, comorbidity, patient preference and access. Erenumab is not a substitute for identifying medication overuse or addressing migraine triggers. The trial is particularly relevant to IANCON's focus on migraine and newer therapies that target disease biology rather than relying solely on traditional preventive mechanisms.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
STRIVE was a large randomized placebo-controlled trial evaluating erenumab, a monoclonal antibody against the CGRP receptor, for prevention of episodic migraine. More than 950 adults were assigned to monthly erenumab 70 mg, 140 mg or placebo for six months. Both doses produced a greater reduction in monthly migraine days than placebo, increased the proportion of patients achieving at least a 50% reduction and reduced use of acute migraine-specific medication. Improvements were also seen in migraine-related physical impairment and everyday activities. Adverse-event rates were similar to placebo in the trial. The study helped establish CGRP-pathway therapy as an effective preventive option for patients with frequent episodic migraine. For HCPs, treatment choice should consider attack burden, prior preventive failures, comorbidity, patient preference and access. Erenumab is not a substitute for identifying medication overuse or addressing migraine triggers. The trial is particularly relevant to IANCON's focus on migraine and newer therapies that target disease biology rather than relying solely on traditional preventive mechanisms.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
